Royal Bank Of Canada Ngm Biopharmaceuticals Inc Transaction History

Royal Bank Of Canada

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.17 - $1.92 $13,722 - $22,519	-11,729 Reduced 91.46%	1,095 $1,000
Q4 2023 Feb 14, 2024	BUY	$0.6 - $1.31 $2,179 - $4,759	3,633 Added 39.53%	12,824 $11,000
Q3 2023 Nov 14, 2023	BUY	$1.05 - $3.37 $4,876 - $15,650	4,644 Added 102.13%	9,191 $9,000
Q2 2023 Aug 14, 2023	BUY	$2.44 - $4.53 $2,579 - $4,788	1,057 Added 30.29%	4,547 $11,000
Q1 2023 May 15, 2023	SELL	$3.72 - $5.4 $7,633 - $11,080	-2,052 Reduced 37.03%	3,490 $14,000
Q4 2022 Feb 14, 2023	BUY	$3.41 - $12.93 $8,003 - $30,346	2,347 Added 73.46%	5,542 $27,000
Q3 2022 Nov 14, 2022	BUY	$12.59 - $17.67 $31,349 - $43,998	2,490 Added 353.19%	3,195 $41,000
Q2 2022 Aug 15, 2022	SELL	$10.58 - $17.5 $17,023 - $28,157	-1,609 Reduced 69.53%	705 $9,000
Q1 2022 May 16, 2022	SELL	$13.81 - $18.6 $46,581 - $62,737	-3,373 Reduced 59.31%	2,314 $36,000
Q4 2021 Feb 14, 2022	BUY	$17.26 - $22.02 $48,189 - $61,479	2,792 Added 96.44%	5,687 $100,000
Q3 2021 Nov 15, 2021	BUY	$20.15 - $26.19 $14,870 - $19,328	738 Added 34.21%	2,895 $60,000
Q2 2021 Aug 16, 2021	BUY	$15.06 - $30.03 $32,484 - $64,774	2,157 New	2,157 $43,000

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.